Annovis Bio, Inc.

Informe acción NYSE:ANVS

Capitalización de mercado: US$80.4m

Annovis Bio Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Annovis Bio de 51.5% y 71.6% por año respectivamente. Se prevé que el BPA crezca en un 51.6% al año. Se espera que la rentabilidad financiera sea de -119.4% en 3 años.

Información clave

51.5%

Tasa de crecimiento de los beneficios

51.62%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs24.8%
Tasa de crecimiento de los ingresos71.6%
Rentabilidad financiera futura-119.40%
Cobertura de analistas

Low

Última actualización27 May 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • May 22

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Artículo de análisis • Jun 25

We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Dec 06

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 17

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Summary In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70% stock drop. The company plans to proceed with a phase 3 trial despite the lack of convincing efficacy data and significant financial constraints. Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 27

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Summary Annovis Bio's Buntanetap shows promising results in treating Alzheimer's and Parkinson's, with significant cognitive and motor function improvements in Phase 2/3 and Phase 3 trials. The drug also improved motor function in Phase 3 Parkinson’s trials, especially in advanced cases and PIGD patients. Buntanetap's mechanism of action targets neurotoxic proteins, offering symptomatic and possibly disease-modifying benefits, making it a valuable IP for combination therapies. Buntanetap showed statistically significant cognitive improvement in Phase 2/3 Alzheimer’s trials, particularly at 15mg and 30mg doses. Unfortunately, its short cash runway can't be ignored. So, I maintain a "hold" rating on ANVS until it secures more long-term financing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Summary Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy in the ITT population among positive post-hoc claims. The company intends to meet with the FDA and discuss an NDA filing, which, we believe, is currently not supported by the available evidence. Financial constraints persist, with ~$4M cash left on the balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jun 30

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Summary Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease. The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern. There is now more certainty that the Phase 2/3 trial in Alzheimer's disease failed to reach its primary endpoints. A recent CFO resignation, lack of funding and the company's wishes to conduct large further trials lead to a Strong Sell rating. Read the full article on Seeking Alpha
Seeking Alpha • May 02

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces financial challenges and may see a significant decline in stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Feb 12

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s symptoms, which could suggest that a majority of patients in the higher 20 mg (higher dose) cohort experienced an improvement. A positive topline readout for the buntanetap 20mg dose would have a positive readthrough to the Alzheimer’s results due in 2Q24. The company has the overhang of needing to raise cash imminently and faces general market skepticism. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Annovis And Alzheimer's Disease: The Best-Laid Plans

Summary Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The primary triggers for Alzheimer's disease are unrelated to amyloid, making it unlikely that Annovis' buntanetap will substantially impact disease progression. Anti-amyloid drugs only slow down the progression of Alzheimer's disease in its early stages in APOE4 carriers and may not be effective in the long-term. Read the full article on Seeking Alpha
Seeking Alpha • Jan 20

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Summary Annovis Bio has two upcoming major catalysts, a phase 2/3 AD clinical trial and a phase 3 PD clinical trial. The investigational drug, Buntanetap, is an enantiomer of a molecule previously tested for AD, with no success. We believe that the likelihood of success for Buntanetap in clinical trials is low, and if the drug fails, Annovis Bio's stock could plummet to or below its cash reserves. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Summary Annovis is expected to report data from Phase 3 and Phase 2/3 trials in Parkinson's and Alzheimer's disease, respectively. The efficacy of Annovis' lead compound, Buntanetap, is difficult to align with its proposed disease-modifying mechanism of action. Annovis has a low market cap and may need to raise capital around the upcoming topline data. Given previously seen stock volatility, I believe a good understanding of the upcoming reporting is in place. Read the full article on Seeking Alpha
Artículo de análisis • Sep 08

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 28

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Summary Results from the phase 3 study, using buntanetap for the treatment of patients with Parkinson's Disease, are expected to be released before the end of 2023. The global Parkinson's Disease drug market is expected to reach $10.4 billion by 2031. Buntanetap is also being explored in an ongoing phase 2/3 study for the treatment of patients with mild to moderate Alzheimer's Disease. Annovis Bio had $16.8 million in cash as of March 31, 2023; enough cash to fund its operations into Q1 of 2024 and will likely need to raise additional cash before end of 2023. Read the full article on Seeking Alpha
Seeking Alpha • Feb 08

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Annovis Bio (NYSE:ANVS) announced Wednesday the EU approval to bring additional 48 trial sites for its Phase 3 study for lead candidate buntanetap in the treatment of Parkinson's disease ("PD"). With 50 clinical trial sites open in the U.S., the clinical-stage biotech is currently enrolling patients for the randomized study, which tests buntanetap 10mg or 20mg vs. placebo in addition to standard of care for six months. "We are pleased to significantly expand our geographic reach with the addition of these EU sites that gives us the ability to efficiently enroll European patients in our study," Chief Executive of Annovis (ANVS) Maria Maccecchini remarked. The company intends to enroll early PD patients in these additional trial sites, spread across countries such as Italy, Spain, Hungary, Poland, and Germany. An interim readout is expected in Q2 2023 if there is a sufficient number of patients who have received two months of therapy. Seeking Alpha contributor Terry Chrisomalis issued a Strong Buy rating on Annovis (ANVS) last year, citing the potential of buntanetap in PD.
Artículo de análisis • Jan 28

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 25

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Clinical stage biotech Annovis Bio (NYSE:ANVS) traded higher in the morning hours Wednesday after the company highlighted "strong" patient enrollment in its Phase 3 trial for Parkinson's disease (PD) candidate buntanetap. "We are very pleased with the pace of enrollment in our Phase 3 study, designed to assess the safety and efficacy of buntanetap in early-stage Parkinson's patients," Chief Executive Maria Maccecchini noted. The company has arranged an interim data analysis in Q2 2023 to see if its original target of 150 patients per arm will be enough to demonstrate a treatment effect. "Based on the current enrollment, the Company anticipates having a sufficient number of patients who have received two months of therapy to conduct an interim analysis in the second quarter of 2023," Annovis (ANVS) added. Buntanetap, formerly known as ANVS401 or Posiphen, has potential not only in PD but also in Alzheimer's, Seeking Alpha contributor Terry Chrisomalis points out.
Seeking Alpha • Oct 06

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Summary Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026. Potential to receive clearance to initiate a phase 3 study using buntanetap for the treatment of patients with Alzheimer's Disease if end of phase 2 meeting goes well. Other drugs in the pipeline include ANVS301 for advanced Alzheimer's Disease/dementia and ANVS405 for traumatic brain injury and stroke.

Previsiones de crecimiento de beneficios e ingresos

NYSE:ANVS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202851-127-181-1792
12/31/2027N/A-85-78-762
12/31/2026N/A-73-62-622
12/31/2025N/A-29-26-26N/A
9/30/2025N/A-25-25-25N/A
6/30/2025N/A-30-25-25N/A
3/31/2025N/A-29-23-23N/A
12/31/2024N/A-25-22-22N/A
9/30/2024N/A-41-23-23N/A
6/30/2024N/A-43-29-29N/A
3/31/2024N/A-48-35-35N/A
12/31/2023N/A-56-40-40N/A
9/30/2023N/A-42-34-34N/A
6/30/2023N/A-33-29-29N/A
3/31/2023N/A-30-26-26N/A
12/31/2022N/A-25-17-17N/A
9/30/2022N/A-24-15-15N/A
6/30/2022N/A-20-13-13N/A
3/31/2022N/A-17-10-10N/A
12/31/2021N/A-14-9-9N/A
9/30/2021N/A-10-8-8N/A
6/30/2021N/A-8-7-7N/A
3/31/2021N/A-8-5-5N/A
12/31/2020N/A-5-4-4N/A
9/30/2020N/A-4-3-3N/A
6/30/2020N/A-3-2-2N/A
3/31/2020N/A-1-1-1N/A
12/31/2019N/A-100N/A
9/30/2019N/A-1N/A-1N/A
6/30/2019N/A-1N/A-1N/A
3/31/2019N/A-1N/A-1N/A
12/31/2018N/A-1N/A-1N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ANVS siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ANVS siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ANVS siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ANVS no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ANVS no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ANVS se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/07 13:14
Precio de las acciones al final del día2026/06/05 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Annovis Bio, Inc. está cubierta por 3 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.
Jason McCarthyMaxim Group